By Derrick Gingery / Email the Author / Jul. 17, 2013
Executive Summary
FDA and stakeholders reiterate that volume cannot be the sole measure of whether a compounder should be regulated like a drug manufacturer; Rep. Griffith pitches potentially using it and other indicators to draw the line.
No comments:
Post a Comment